The startup develops drug delivery technology that enables the transport of therapeutic agents across the blood-brain barrier to target incurable neuronal diseases. This platform enhances the efficacy of treatments for patients suffering from central nervous system disorders by ensuring precise drug delivery.
Funding
$9.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FTIFounders
Product
Problem
Effective treatment of central nervous system (CNS) disorders is hindered by the blood-brain barrier (BBB), which restricts the passage of therapeutic agents into the brain. Many potentially effective drugs cannot reach the brain in sufficient concentrations to have a therapeutic effect.
Solution
Braizon Therapeutics develops a drug delivery platform, Brain Access®, designed to transport a wide range of therapeutic molecules across the blood-brain barrier. The technology utilizes surface-modified polymer nanoparticles with ligands that facilitate transcytosis across the BBB. This approach allows for increased drug concentrations in the brain, improved therapeutic efficacy, and the potential to treat previously untreatable CNS diseases. The Brain Access® platform can be customized with different ligands to target specific receptors on the BBB, including both GLUT1 and transferrin receptors (TfR), enabling versatility in drug delivery strategies.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies, as well as academic institutions, focused on developing novel therapies for central nervous system disorders.
Features
- Nanoscale, biodegradable carriers that extend drug circulation time and protect drugs from efflux mechanisms at the BBB
- Surface modification with ligands (navigation molecules) to target specific receptors (GLUT1 and TfR) on the BBB for enhanced transcytosis
- Compatibility with a wide range of therapeutic molecules, including small molecules, nucleic acid drugs, antibodies, and peptides
- Customizable polymer structures to optimize drug encapsulation and release
- Potential for both extracellular and intracellular drug release, depending on the target location and disease mechanism
- Demonstrated brain parenchyma diffusion with TfR ligand-modified micelles